7 / 28
Mechanisms of resistance to AR directed therapies
AR-dependent and ligand-dependent pathways
- AR amplification
- AR mutations
(non-androgenic ligands)
- Intratumoral androgen synthesis
- Enzymatic mutations leading to increased androgen synthesis
AR-dependent and ligand-independent pathways
- AR splice variants
AR and ligand independent pathways
- GR cross-stimulating AR target genes
- Alternate non-AR pathways (PTEN, NE transformation)
Rodriguez-Vida,Drug design, 2015